Background: Kidney transplantation has significantly improved survival and quality of life of patients with end-stage renal disease and is considered the best form of renal replacement therapy. Rabbit anti-thymocyte globulin (rATG) has commonly been reserved for high immunologic risk patients and the resulting profound depression in immune response is associated with an increased risk for infection. Methods: A retrospective cohort of patients transplanted from June 2012 to December 2014 was done to evaluate the short- and long-term outcome and efficacy of low dose rATG versus basiliximab as induction. CNI-based triple immunosuppression was given to the majority of patients. Results: Among 165 patients in the study, 131 were given basiliximab and 34 were given low dose rATG (1-1.5 mg/kg/day for 3 days). The two groups were similar in mean age, native kidney disease, and cytomegalovirus (CMV) status. Higher proportion of patients who received rATG had positive panel reactive antibody (P=0.0003), higher human leucocyte antigen mismatches (P=0.0023), and non-related donors (P=0.025). Low dose rATG and basiliximab as induction therapy resulted in comparable outcomes including DGF, graft function, proteinuria, incidence of acute rejection and post-transplant malignancy. Incidence of infection was significantly higher in basiliximab group at 3-year post-KT: 11.5% vs. 0, P=0.04. CMV infection occurred very low at an overall rate of 0.6% at 1- and 3-year post-KT. Graft and patient survival at 5-year post-KT were 96.9% vs. 97.1%, P=0.99 and 99% vs. 100%, P=0.57, respectively. Conclusions: Both low dose rATG and basiliximab induction resulted in excellent long-term outcomes. Low dose rATG was not associated with higher infection rates and can be used safely in standard risk patients.